Verastem, Inc.
$6.52
▲
1.44%
2026-04-21 10:11:01
www.verastem.com
NCM: VSTM
Explore Verastem, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$557.75 M
Current Price
$6.52
52W High / Low
$11.24 / $4.01
Stock P/E
—
Book Value
$0.74
Dividend Yield
—
ROCE
-97.68%
ROE
-14.8%
Face Value
—
EPS
$-3.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
102
Beta
0.43
Debt / Equity
152.4
Current Ratio
3.09
Quick Ratio
3.07
Forward P/E
-4.49
Price / Sales
15.09
Enterprise Value
$348.58 M
EV / EBITDA
-2.06
EV / Revenue
11.28
Rating
Strong Buy
Target Price
$16.38
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Hoth Therapeutics, Inc. | $0.74 | — | $13.96 M | — | -200.97% | -1.91% | $2.12 / $0.49 | $0.4 |
| 2. | Rein Therapeutics Inc. | $1.83 | — | $51.31 M | — | -121.99% | -1.4% | $2.4 / $1.02 | $-1.02 |
| 3. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 4. | Kyntra Bio, Inc. | $7.34 | 0.16 | $29.62 M | — | -50.18% | -143.52% | $12.6 / $4.85 | $-7.42 |
| 5. | CRISPR Therapeutics AG | $57.69 | — | $5.56 B | — | -31.41% | -30.18% | $78.48 / $33.03 | $20.04 |
| 6. | ImageneBio, Inc. | $6 | — | $65.99 M | — | -34.18% | -68.91% | $18 / $3.94 | $11.91 |
| 7. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 17.54 M | 11.24 M | 2.14 M | 0 M | 0 M | — |
| Operating Profit | -41.48 M | -40.72 M | -43.76 M | -44.17 M | -31.59 M | — |
| Net Profit | -32.92 M | -98.52 M | -25.93 M | -52.1 M | -64.55 M | — |
| EPS in Rs | -0.37 | -1.12 | -0.3 | -0.59 | -0.73 | -0.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 30.91 M | 10 M | 0 M | 2.6 M |
| Operating Profit | -170.13 M | -114.96 M | -92.08 M | -72.94 M |
| Net Profit | -209.47 M | -130.64 M | -87.37 M | -73.81 M |
| EPS in Rs | -2.38 | -1.49 | -0.99 | -0.84 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 246.44 M | 101.54 M | 149.72 M | 95.05 M |
| Total Liabilities | 189.25 M | 130.43 M | 92.34 M | 47.66 M |
| Equity | 57.2 M | -28.89 M | 57.37 M | 47.39 M |
| Current Assets | 223.41 M | 94.96 M | 143.68 M | 92.87 M |
| Current Liabilities | 72.27 M | 30.97 M | 26.38 M | 21.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -137.51 M | -104.77 M | -86.46 M | -63.67 M |
| Investing CF | -9.62 M | 59.97 M | -44.45 M | 66.19 M |
| Financing CF | 263.31 M | 54.78 M | 134.19 M | 51.78 M |
| Free CF | -147.13 M | -104.8 M | -86.46 M | -63.67 M |
| Capex | -9.62 M | -0.03 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -49.53% | -18.36% | — | — |
| Profit Margin % | -1306.37% | — | -2843.3% | — |
| Operating Margin % | -1149.56% | — | -2809.59% | — |
| Gross Margin % | 100% | — | 100% | — |
| EBITDA Margin % | -1258.64% | — | -2756.43% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-06-01 | 1:0.0833333 |